A Study on Disease Awareness and Treatment Compliance of Heart Failure Patients
- Conditions
- Heart Failure
- Interventions
- Other: Questionnaires
- Registration Number
- NCT05180396
- Lead Sponsor
- AstraZeneca Turkey
- Brief Summary
The AWARENESS HF-PD is a cross-sectional, multicenter, survey-based study. Cases who were admitted to the outpatient clinic and hospitalized with the diagnosis of Heart Failure (Acute and Chronic) will be included in the study.
- Detailed Description
Data entry personnel to be assigned at the centers throughout the study will apply a questionnaire consisting of different questions to patients referred to them by clinicians with the diagnosis of HF. In addition, clinical features of HF from the current file of the cases (NYHA, comorbid conditions, comorbid diseases, blood pressure, heart rate, latest biochemistry (BNP/NTproBNP if available), hematology test results, most recent ECG, most recent echocardiography , coronary angiography report, if any) will be recorded. No additional examination/procedure will be performed for the study, only the data of the examinations requested by the clinician in routine clinical practice will be entered. A total of 200 patients from 3 centers will be included in this study over a six-month period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 200
- Male or female patients aged 18 and over
- Patients diagnosed with acute or chronic heart failure
- Patients who agreed to participate in the study
- Patients who stated that they did not agree to participate in the study
- Patients who were not diagnosed with Heart Failure or whose diagnosis was changed or not confirmed during the index application
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Cases with the diagnosis of Heart Failure (Acute and Chronic) Questionnaires Application of a questionnaire consisting of different questions to patients.
- Primary Outcome Measures
Name Time Method Disease Information 6 months At the end of the six-month recruitment period disease information, treatment compliance, and awareness assessment will be performed on all included patients.
Demographics 6 months At the end of the six-month recruitment period, demographic, symptoms, clinical follow-up status, d will be performed on all included patients.
- Secondary Outcome Measures
Name Time Method HF Percutaneous Intervention / Operation History (CRT, ICD, CRT-DI, Pacemaker, PKG, CABG and Heart Valve Operations) 6 months CRT, ICD, CRT-DI, Pacemaker, PKG, CABG and Heart Valve Operations
HF Risk Factors (BMI, Diabetes, Hypertension, HLP, Tobbaco Use, CV Hereditary, Menapause, MI History and History of CMP in family) 6 months BMI, Diabetes, Hypertension, HLP, Tobbaco Use, CV Hereditary, Menapause, MI History and History of CMP in family
HF ECHO Results (EF, LA, SID, Mitral Defficiency, SPAB, DID, Septum, SEG Muscle Weakness, Trial Defficiency) 6 Months (EF, LA, SID, Mitral Defficiency, SPAB, DID, Septum, SEG Muscle Weakness, Trial Defficiency)
HF Comorbidities (CAD, AF, COPD, CRF, Anemia, Iron Defficiency, Hypo- Hypertiroidy, OSAS) 6 months (CAD, AF, COPD, CRF, Anemia, Iron Defficiency, Hypo- Hypertiroidy, OSAS
HF Laboratory Results (Glucose, BUN, Creatinine, GFR, Sodium, Potassium, Nt-ProBNP, ALT, AST, ALP, HS-CRP, cTN, Hemoglobine, WBC, Ferritine, TSAD, LDL, tryglyceride, ST3, GGT, INR, ST4) 6 months Glucose, BUN, Creatinine, GFR, Sodium, Potassium, Nt-ProBNP, ALT, AST, ALP, HS-CRP, cTN, Hemoglobine, WBC, Ferritine, TSAD, LDL, tryglyceride, ST3, GGT, INR, ST4)
Trial Locations
- Locations (3)
Akdeniz University Medical Faculty
🇹🇷Antalya, Turkey
Kahramanmaraş Sütçü İmam University Medical Faculty
🇹🇷Kahramanmaraş, Turkey
Mersin University Medical Faculty
🇹🇷Mersin, Turkey